Pipeline-focused public companies
Find biotechnology and pharmaceutical companies by market profile and drug-development maturity, then open each ticker for its stock, pipeline and catalyst research page.
| Company | Price | Market cap | Pipeline | Next catalyst | Open |
|---|---|---|---|---|---|
| NK NKGNNKGen Biotech | $0.01+0.0% | $7.8M | 4 assetsStage unavailable | No dated catalyst | |
| NK NKTRNektar Therapeutics | $74.02-0.7% | $2.53B | 22 assetsPhase 3 | Rezpegaldesleukin (NKTR-358) Phase 2b · Data readout | |
The screener is the parent research index for individual ticker pages such as CAPR. Filter the biotech company universe here, then open a company to review its stock snapshot, drug assets, clinical stage and dated catalysts. Quote information is a cached market snapshot and may be delayed.
| $2.66+7.7% |
| $190.5M |
8 assetsPhase 1 |
NKX019 (CAR NK cell therapy)Phase 1 · Data readout |
| NL NLTXNeoleukin Therapeutics | $38.63+1.7% | — | 1 assetsStage unavailable | No dated catalyst |
| NM NMRANeumora Therapeutics | $1.63+7.6% | $306.3M | 7 assetsPhase 1b | NMRA-511Phase 1b · Data readout |
| NR NRIXNurix Therapeutics | $26.72-1.2% | $2.77B | 13 assetsPhase 1 | Zelebrudomide (NX-2127)Phase 1a · Data readout |
| NR NRXPNRX Pharmaceuticals | $3.56+1.4% | $154.1M | 9 assetsStage unavailable | No dated catalyst |
| NT NTLAIntellia Therapeutics | $12.84+3.2% | $1.80B | 6 assetsStage unavailable | No dated catalyst |
| NT NTRANatera | $332.03+2.2% | $47.86B | 6 assetsStage unavailable | No dated catalyst |
| NU NUVBNuvation Bio | $6.93+1.5% | $2.43B | 12 assetsPDUFA | IBTROZI (Taletrectinib) (ROS1 inhibitor)PDUFA · Approval decision |
| NU NUVLNuvalent | $123.96+0.0% | $9.81B | 7 assetsStage unavailable | No dated catalyst |
| NV NVAXNovavax | $8.94+6.2% | $1.47B | 9 assetsStage unavailable | No dated catalyst |
| NV NVCRNovoCure Limited | $17.10-3.8% | $1.99B | 8 assetsPDUFA | Stereotactic radiosurgery (SRS) w/ NovoTTF-200MPDUFA · Approval decision |
| NV NVCTNuvectis Pharma | $23.56+0.9% | $767.6M | 4 assetsPhase 1b | NXP900Phase 1b · Data readout |
| NV NVONovo Nordisk | $46.74+1.3% | $206.69B | 7 assetsStage unavailable | No dated catalyst |
| NV NVSNovartis | $158.86+1.7% | $301.95B | 19 assetsPhase 3 | Delpacibart Etedesiran (Del-desiran) (AOC 1001)Phase 3 · Data readout |
| NW NWBONorthwest Biotherapeutics | $0.17+0.0% | $290.0M | 1 assetsStage unavailable | No dated catalyst |
| NX NXTCNextCure Inc | $6.29+0.6% | $28.8M | 7 assetsPhase 1 | LNCB74 (B7-H4 ADC)Phase 1 · Data readout |
| OC OCGNOcugen | $1.39+0.0% | $471.4M | 8 assetsPhase 3 | OCU410STPhase 2/3 · Data readout |
| OC OCULOcular Therapeutix | $11.08-0.1% | $2.43B | 8 assetsStage unavailable | No dated catalyst |
| OD ODTXOdyssey Therapeutics | $26.39+7.0% | $1.27B | 1 assetsStage unavailable | No dated catalyst |
| OG OGENOragenics, Inc. | $0.53-2.8% | $2.4M | 1 assetsPhase 2 | ONP-002Phase 2 · Data readout |
| OK OKUROnKure Therapeutics, Inc. | $3.94+0.3% | $159.6M | 5 assetsPhase 1 | OKI-219 +/- Fulvestrant or TrastuzumabPhase 1 · Data readout |
| OK OKYOOKYO Pharma | $1.54+2.7% | $80.8M | 1 assetsStage unavailable | No dated catalyst |
| OL OLMAOlema Pharmaceuticals | $10.69-1.9% | $935.3M | 8 assetsPhase 3 | OP-1250 (palazestrant) (CER antagonist) Phase 3 · Data readout |
| OM OMEROmeros Corporation | $19.27+3.4% | $1.39B | 13 assetsApproved | No dated catalyst |
| OM OMGAOmega Therapeutics | $0.14+0.0% | $7.9M | 1 assetsStage unavailable | No dated catalyst |
| ON ONCBeOne Medicines | $374.47+1.4% | $42.36B | 32 assetsApproved | BGB-45035 (IRAK4 Degrader)Phase 1/2 · Data readout |
| ON ONCTOncternal Therapeutics | $0.53+0.0% | $1.6M | 6 assetsStage unavailable | No dated catalyst |
| ON ONCYOncolytics Biotech | $0.84+5.2% | $107.5M | 10 assetsPhase 2 | Pelareorep + Bevacizumab + FOLFIRI (Oncolytic Virus)Phase 2 · Data readout |
| OP OPKOPKO Health | $1.48+1.4% | $1.10B | 12 assetsPhase 1/2 | MDX2301 (Tetravalent Bispecific Antibody)Phase 1 · Data readout |
| OP OPTNOptiNose | $9.60+0.0% | $97.2M | 2 assetsStage unavailable | No dated catalyst |
| OR ORICORIC Pharmaceuticals | $14.20+2.3% | $1.47B | 8 assetsPhase 1b | Enozertinib (ORIC-114)Phase 1b · Data readout |
| OR ORKAOruka Pharmaceuticals | $107.96+3.0% | $7.15B | 6 assetsPhase 2b | ORKA-001Phase 2a · Data readout |
| OR ORMPOramed Pharmaceuticals | $4.81+0.4% | $200.1M | 2 assetsStage unavailable | No dated catalyst |
| OR ORTXOrchard Therapeutics | $16.70+0.0% | — | 4 assetsStage unavailable | No dated catalyst |
| OS OSTXOS Therapies | $1.59+0.6% | $73.3M | 2 assetsPhase 2b | OST-HER2Phase 2b · Data readout |
| OT OTLKOutlook Therapeutics | $0.65-4.3% | $157.1M | 1 assetsApproved | No dated catalyst |
| OV OVIDOvid Therapeutics | $2.80+2.2% | $546.8M | 11 assetsPhase 2 | OV329 (GABA-AT inhibitor)Phase 2 · Data readout |
| PA PALIPalisade Bio | $2.10+1.9% | $366.0M | 3 assetsStage unavailable | No dated catalyst |